Trial Profile

A Phase 1, Multi-center, Parallel, Open-label, Pharmacokinetic, Safety, and Tolerability Study of Venglustat Given as a Single Dose in Adult Participants With Mild, Moderate, and Severe Hepatic Impairment and in Matched Participants With Normal Hepatic Function

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Venglustat (Primary)
Indications Fabry's disease; Gaucher's disease; Gaucher's disease type III; GM2 gangliosidoses; Polycystic kidney disease
Focus Pharmacokinetics
Sponsors Sanofi

01 Feb 2024 Status changed from recruiting to completed.
10 Jan 2024 Planned End Date changed from 20 Dec 2023 to 23 Jan 2024.
10 Jan 2024 Planned primary completion date changed from 20 Dec 2023 to 23 Jan 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com